Skip to main content

Table 1 Patient’s demographic and clinical characteristics (enrolled population, n = 149)

From: Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

Characteristic

 

NEPA plus 1-day Dex

No. (%)

Age (years)

 Median

48

 

 min-max

25–76

 

 Age < 50 years

 

82 (55)

Height (cm)

 Mean

162.2

 

 SD

6.4

 

Weight (kg)

 Mean

66.9

 

 SD

14.5

 

ECOG performance status

 0

 

146 (98)

 1

 

3 (2.0)

Chemotherapy regimen

 AC

 

40 (26.8)

 EC

 

100 (67.1)

 FEC

 

5 (3.4)

 Other/missing

 

4 (2.7)

Alcohol consumption

 No

 

88 (59.1)

 Occasionallya

 

42 (28.2)

 Regularly

 

16 (10.7)

 Missing

 

3 (2.0)

History of motion sickness

 

47 (31.5)

History of pregnancy-related morning sickness

 

57 (38.3)

  1. NEPA fixed-dose combination of netupitant and palonosetron, Dex dexamethasone, SD standard deviationm, AC anthracycline (i.e., doxorubicin) and cyclophosphamide, EC epirubicin and cyclophosphamide, FEC fluorouracil, epirubicin, and cyclophosphamide
  2. aIt is defined as drinking one or two glasses per week